The Role of Focal Therapy in a Prostate Cancer Treatment Platform
Thursday, September 12th 2019
We are pleased to invite you to participate in our 4th symposium on localized prostate cancer.
For 5 years, we have created a radiological platform dedicated to urology. Since then, radiologists and urologists have been working closely together on an independent radiological interface to provide patients with high-quality diagnostic tools, particularly for the prostate. These resources are validated by multidisciplinary and radio-pathological meetings, a database as well as collaborations at the scientific level developed in partnership with the SIPC (Swiss International Prostate Center).
This avant-garde project involving urologists and radiologists is available to all urologists and also to private clinics and the HUG.
This year, we will study the role of focal therapy of localized prostate cancer in a multidisciplinary group. What indications, what modalities, for which localization as well as different local and foreign clinical experiences will be the highlights of this 4th symposium.
The symposium will take place in Geneva on Thursday, September 12th, from 5:30 pm to 8:45 pm, at the Hôtel Métropole, followed by a dinner.
Save the date !
We hope to see many of you!
Martina MARTINS FAVRE Stefano REGUSCI
FMH Radiologue FMH Urologue
Continuing Education Points: Radiology, Urology, Internal Medicine
17h30 : Welcome - drinks
18h00 : Introduction - Dr. Martins Favre and Dr. Regusci (Geneva) - Philips Reference Center
18h05 : Personalized approach “à la carte” - Prof Barret - Montsouris
18h30 : MRI in the follow-up of focal therapies - Prof Rafaelle Pena - Salpétrière
18h50 : Prostate MRI and genetics – Prof Rafaelle Pena - Salpétrière
19h10 : Dutch experience in the treatment by electroporation - Prof Théo de Reijke - Amsterdam
19h30 : Comparison radical prostatectomy and focal therapy - Prof Baco - Oslo
19h50 : The role of interstitial laser in focal therapy - Dr. Regusci - Geneva
20h00 : Development of a focal therapy program in a private center – importance of multidisciplinary approach and network - Dr. P. Henry - Besancon
20h20 : To define - Pr F. Debruyne - Holland
20h40 : Conclusion, Discussion all invitees + videoconference - Pr P. Puech - CHU Lille
21h00 : Diner
▪ Dr. Martina Martins Favre, Radiologue FMH, Imagerive, Rue de Rive 1, CH-1204 Genève
▪ Dr. Stefano Regusci, Urologue FMH, Chemin Beau Soleil 12, CH-1206 Genève
▪ Prof Eric Barret, Urologue, Institut Mutualiste Montsouris, 42 Bd Jourdan, FR-75014 Paris
▪ Profr Raphaëlle Renard-Penna, Service de radiologie, Hôpital La Pitié-Salpêtrière, 47 Bd de l’Hôpital, FR-75013 Paris
▪ Prof Théo de Reijke, Centre médical Universitaire, Amsterdam
▪ Prof Edouard Baco, Département Urologie, Hôpital Universitaire d’Oslo, Norvège
▪ Dr. Pierre-Charles Henry, Chirurgien Urologue, 33 Chemin des Tilleroyes, FR-25000 Besançon
▪ Prof Frans Debruyne, Urologue et directeur médical , Andros Mannenkliniek Arnhem, Holland
▪ Prof Philippe Puech, PHD Chef de Service en image Néphro-urologique, Hôpital Universitaire de Lille, Rue Michel Polonovski, FR-59037 Lille
▪ Dr. Massimo Valerio Urologue FMH, CHUV Rue du Bugnon 46, CH-1011 Lausanne
On registration the next day September 13th at 9am live demonstration of laser therap
Risk of biochemical recurrence based on extent and location of positive surgical margins after robot-assisted laparoscopic radical prostatectomy
There are no published studies on the simultaneous effect of extent and location of positive surgical margins (PSMs) on biochemical recurrence (BCR) after robot-assisted laparoscopic prostatectomy (RALP). The aim was to report the incidence, extent, and location of PSMs over the inclusion period as well as the rates of BCR and cancer-related mortality, and determine if BCR is associated with PSM extent and/or location.
Retrospective review of 530 consecutive patients who underwent RALP between 2003 and 2012. Kaplan-Meier (KM) survival analyses and Cox regressions were performed to determine variables associated with BCR.
For the 530 operated patients, evaluated at a median of 92 months (IQR, 87–99), PSMs were observed in 156 (29%), of which 24% were focal. Out of 172 PSMs, 126 (73%) were focal and 46 (27%) were extensive. The KM survival using BCR as endpoint was 0.81 (CI, 0.78–0.85) at 5 years and was 0.67 (CI, 0.61–0.72) at 10 years; and using cancer-related mortality as endpoint was 0.99 (CI, 0.99–1.00) at 5 years and 0.95 (CI, 0.92–0.98) at 10 years. Multi-variable analysis revealed the strongest predictors of BCR to be Gleason score ≥ 8 (HR = 7.97; CI, 4.38–14.51) and 4 + 3 (HR = 3.88; CI, 2.12–7.07), lymph nodes invasion (HR = 3.42; CI, 1.70–6.91), pT stage 3b or 4 (HR = 3.07; CI, 1.93–4.90), and extensive apical PSMs (HR = 2.62; CI, 1.40–4.90) but not focal apical PSMs (HR = 0.86; CI, 0.49–1.50; p = 0.586).
Extensive apical PSMs significantly increased the risk of BCR, independently from pT stage, Gleason score and lymph nodes invasion, while focal apical PSMs had no significant effect on BCR.
Or as pdf:
SIPC will take part at the annual meeting of the Swiss Urology Society from 6 to 8 September 2017 in Lugano, with this presentation:
Correlation between template guided transperineal biopsies and MRI diagnostic imaging
M. Martins Favre, C-H Rochat, I. Szalay-Quinodoz I, A Caviezel, S Tran, G-A De Boccard, S Rohner, S Regusci